Zacks Investment Research
07 Aug 2026, 15:46 UTC · 1h ago
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
07 Aug 2026, 15:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Moderna lowered its 2026 cost-of-sales and R&D guidance, reducing projected cash costs by $0.2 billion to approximately $4 billion. — Lowering operating expenses directly improves the bottom line and reduces the cash burn rate for a loss-making biotech company.
+0.40Moderna reported second-quarter 2026 revenues of $145 million, exceeding the Zacks Consensus Estimate of $126.60 million. — A revenue beat suggests stronger-than-expected current demand or better execution of sales strategies.
+0.30The seasonal flu vaccine mRNA-1010 received a unanimous U.S. advisory committee recommendation ahead of its August 5 PDUFA date. — Positive regulatory progress for a core pipeline product increases the probability of approval and future revenue streams.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Moderna reiterated its 2026 target of up to 10% revenue growth, despite anticipating potential declines in COVID vaccination rates. — Steady guidance provides some stability, but the admission of declining COVID rates acts as a headwind.
+0.10Which stocks this story touches
The company beat revenue estimates and lowered its projected operating expenses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
